BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of healthโข by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com. See community guidelines here: bit.ly/4vTpKjz
Unlock the market timeline & signal feed
1,746 signals in the last 90 days.
The order this company entered each market โ oldest to newest
Register here for the webinar
Register here for the webinar
Sign up to see the full signal feed
How BD's international expansion compares to its competitors
BDYouBars show relative size across the companies compared.
5 metrics| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 BDYou | 61 | 0 | +22% | 1.6k | 36 |
Scaling fast โ 1,053 roles opened in the last 90 days, up 124% vs the prior period. Engineering-led and concentrated in United States.
Luxembourg, Luxembourg, Luxembourg ยท yesterday
Field Marketing Associate France & Benelux (Project)
Tijuana, Baja California, Mexico ยท yesterday
SUPERVISOR DE QUEJAS EMI
Amsterdam, North Holland, Netherlands ยท yesterday
Field Marketing Associate France & Benelux (Project)
63 technologies detected across the stack.
182 active campaigns across 153 markets.
Ended
Ended
Ended7 mentions in the last 90 days.
California Department of Public Health approved Envetec's GENERATIONS technology for biohazardous waste treatment, expanding the company's U.S. regulatory footprint to include California, New York, Texas, and Massachusetts.
Alteogen reported H1 2026 revenue of 140.5 billion won, up 37% YoY, driven by Hybrozyme platform licensing deals with GSK's Tesaro and Biogen, plus expanding sales of MSD's Keytruda subcutaneous formulation.
Becton, Dickinson (BDX) will announce Q4 earnings on August 6th before market open, with consensus EPS estimate of $3.14 (-20.7% Y/Y) and revenue estimate of $4.89B (-17.0% Y/Y).
Unlock verified emails & direct dials
Free ยท No credit card needed
Quick answers about BD's business, markets, and growth signals.
โWe reach accounts the week they land in-market โ not the quarter after.โ
Book a walkthrough of the movement map with our team.
Pubrio turns expansion signals across 200+ markets into one live graph, so revenue teams see which companies are entering new markets, and act on the timing.
ยฉ 2026 Pubrio. All rights reserved.
